MCID: TRP003
MIFTS: 22

Triple-Receptor Negative Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Triple-Receptor Negative Breast Cancer

MalaCards integrated aliases for Triple-Receptor Negative Breast Cancer:

Name: Triple-Receptor Negative Breast Cancer 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0060081

Summaries for Triple-Receptor Negative Breast Cancer

MalaCards based summary : Triple-Receptor Negative Breast Cancer is related to breast cancer and malignant glioma. An important gene associated with Triple-Receptor Negative Breast Cancer is LINC-ROR (Long Intergenic Non-Protein Coding RNA, Regulator Of Reprogramming
LincRNA-RoR is upregulated in TNBC and in metastatic disease and knockdown restores miR-145 expression.The lincRNA-RoR/miR-145/ARF6 pathway is critical to TNBC metastasis and could serve as biomarkers or therapeutic targets for improving survival.
Dysfunction Pattern: ), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Pembrolizumab and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include breast and brain.

Related Diseases for Triple-Receptor Negative Breast Cancer

Graphical network of the top 20 diseases related to Triple-Receptor Negative Breast Cancer:



Diseases related to Triple-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Triple-Receptor Negative Breast Cancer

Drugs & Therapeutics for Triple-Receptor Negative Breast Cancer

Drugs for Triple-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pembrolizumab Approved Phase 3 1374853-91-4
2
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
3
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
4
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
5
Gemcitabine Approved Phase 2 95058-81-4 60750
6
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
7
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
8
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
9
Epirubicin Approved Phase 2 56420-45-2 41867
10
Everolimus Approved Phase 2 159351-69-6 6442177
11
Fluorouracil Approved Phase 2 51-21-8 3385
12
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
13
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
14 Albumin-Bound Paclitaxel Phase 2
15 Antimitotic Agents Phase 2
16 Antineoplastic Agents, Phytogenic Phase 2
17 Angiogenesis Inhibitors Phase 2
18 Angiogenesis Modulating Agents Phase 2
19 Alkylating Agents Phase 2
20 Anti-Bacterial Agents Phase 2
21 Antibiotics, Antitubercular Phase 2
22 Antifungal Agents Phase 2
23 Anti-Infective Agents Phase 2
24 Antimetabolites Phase 2
25 Antimetabolites, Antineoplastic Phase 2
26 Antineoplastic Agents, Alkylating Phase 2
27 Antirheumatic Agents Phase 2
28 Immunosuppressive Agents Phase 2
29 Topoisomerase Inhibitors Phase 2
30
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
31 Mitogens Phase 2
32 Protein Kinase Inhibitors Phase 2
33 taxane Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02954874 Phase 3
2 EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients Completed NCT00448305 Phase 2 EndoTAG-1 + paclitaxel;EndoTAG-1;Paclitaxel
3 Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer Completed NCT00246571 Phase 2 SU011248;Chemotherapy
4 Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer Active, not recruiting NCT00499603 Phase 2 Paclitaxel;5-Fluorouracil;Epirubicin;Cyclophosphamide;RAD001
5 Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer Terminated NCT00739063 Phase 2 Tarceva
6 A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations Terminated NCT02299635 Phase 2 PF-03084014;PF-03084014;PF-03084014

Search NIH Clinical Center for Triple-Receptor Negative Breast Cancer

Genetic Tests for Triple-Receptor Negative Breast Cancer

Anatomical Context for Triple-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Triple-Receptor Negative Breast Cancer:

41
Breast, Brain

Publications for Triple-Receptor Negative Breast Cancer

Articles related to Triple-Receptor Negative Breast Cancer:

(show all 12)
# Title Authors Year
1
Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. ( 29235566 )
2018
2
The unmet need for effective treatment of triple-receptor negative breast cancer. ( 25768894 )
2014
3
Mesothelin expression and survival outcomes in triple receptor negative breast cancer. ( 23810431 )
2013
4
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. ( 21800293 )
2012
5
Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. ( 22359359 )
2012
6
Triple receptor-negative breast cancer: imaging and clinical characteristics. ( 22826413 )
2012
7
Capecitabine in operable triple receptor-negative breast cancer: A subgroup analysis of a randomized phase III trial. ( 27958045 )
2011
8
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. ( 21233401 )
2011
9
Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? ( 20580045 )
2010
10
Survival among women with triple receptor-negative breast cancer and brain metastases. ( 19150943 )
2009
11
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. ( 19047281 )
2009
12
Advances in triple receptor-negative breast cancer. ( 18277956 )
2007

Variations for Triple-Receptor Negative Breast Cancer

Expression for Triple-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Triple-Receptor Negative Breast Cancer.

Pathways for Triple-Receptor Negative Breast Cancer

Pathways related to Triple-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 HOTAIR LINC-ROR

GO Terms for Triple-Receptor Negative Breast Cancer

Sources for Triple-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....